Research Highlights

Ion channel VRAC enhances immune response against viruses by transporting the messenger substance cGAMP from cell to cell

IMMUNITY VRAC/LRRC8 chloride channels do not only play a decisive role in the transport of cytostatics, amino acids and neurotransmitters. They can also transport the important messenger substance cGAMP from cell to cell and thus strengthen the immune response to infections with DNA viruses. This has now been demonstrated by Prof. Thomas Jentsch, who originally discovered LRRC8/VRAC channels and works at the Leibniz Research Institute for Molecular Pharmacology (FMP) and the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, together with colleagues from Shanghai led by Prof. Hui Xiao. Since cGAMP is always formed when cells detect DNA outside their nucleus, the discovery is potentially of great importance also for other pathologies such as cancer. The work has now been published in the scientific journal "Immunity".

Upon infection of cells with a DNA virus (left), viral DNA binds to the enzyme cGAS which then synthesizes the messenger molecule cGAMP. The present work shows that cGAMP can leave the cell through the anion channel VRAC and diffuses to non-infected cells in the vicinity. After entering the cell – again through VRAC – it binds to a receptor called STING and stimulates indirectly the synthesis of interferon, which leaves the cell and suppresses, after binding to a receptor, the propagation of the virus (left cell). This provides a powerful amplification of the innate immune response against DNA viruses.

If DNA viruses such as herpes simplex - the coronavirus, being an RNA virus, does not belong to this group! - infect human cells; this does not go unnoticed. In the cell interior, the so-called cytoplasm, DNA has no place. Thus, if DNA is detected there messenger substances are formed and begin to sound the alarm. The foreign DNA binds to the enzyme cGAS, which synthesizes the 'second messenger' cGAMP. By binding to a receptor called STING, cGAMP activates a cellular signaling cascade that triggers the production of interferons and other factors of the innate immune system. This mechanism has also been observed in tumor cells, in which DNA fragments are released from the nucleus into the cytoplasm, as well as in some bacterial infections.

cGAMP is a highly topical messenger substance

Research on cGAMP has exploded in recent years, partly because it not only acts in the cell where it is produced, but also passes on to other cells. However, it remains unclear how this may happen. In cells that directly contact each other, cGAMP can pass through cell-connecting channels known as "gap junctions".  But what about cells that are not in the immediate vicinity?
Researchers led by Prof. Hui Xiao from the Institut Pasteur Shanghai had suspected that further transport pathways must play a role and came across the volume-regulated anion channel VRAC - the ion channel discovered in 2014 by Prof. Thomas Jentsch and his team, and in parallel by Prof. Zhaozhu Qiu (now Johns Hopkins University), who also contributed to the publication in “Immunity”.  Together, the German-Chinese research team was able to demonstrate with a whole variety of methods that VRAC transports cGAMP both out of the producing cell and into the recipient cell. This leads to the production of interferons in cells that are not infected, thereby strengthening the immune response.
"We now know that VRAC definitely transports cGAMP" says Thomas Jentsch about this significant discovery. "We didn't know this function yet, but it fits well with our previous findings on VRAC, namely that it not only transports chloride, but also other small organic molecules, for instance neurotransmitters, amino acids and cytostatics. The dependence of the cGAMP transport on the subunit LRRC8E - VRAC is always composed of several subunits - which we have now observed, agrees well with our earlier findings, which showed that this subunit supports the transport of glutamate, which is also negatively charged.”
The uptake of the messenger substance by VRAC was verified by various cell culture experiments and by electrophysiological approaches. In one experiment, for example, cells were infected with a DNA virus and separated from healthy cells using a filter. The virus infection could not be transmitted - but an interferon response was also observed in the non-infected cells.
Finally, experiments with knock-out mice generated in Berlin which lacked the VRAC subunit LRRC8E provided compelling evidence: if the rodents were infected with herpes viruses, a much higher viral load and lower interferon release were observed than in unmodified control animals. "This was exactly what we expected, because the messenger substance could no longer be transferred from infected cells to neighboring cells due to the absence of the channel. Since this transfer normally strengthens the immune response." explains Professor Jentsch. " the lack of cGAMP-transporting VRAC greatly reduces the defense mechanisms against such viruses.”

New strategies against DNA viruses and cancer
The discovery of this new role of VRAC in the body’s defense system against DNA viruses, a new addition to the many important functions of VRAC, will attract even more attention to this ion channel. The researchers assume that VRAC might play a similar role in cancer. Indeed, others have recently shown in animal experiments that cGAMP transport from cancer cells to neighboring host cells enhanced the immune response against tumors - but how cGAMP is transported had remained unclear.
Besides VRAC and gap junctions, a folate transporter also transports cGAMP across the membrane, as was shown last year. However, VRAC is found in more cell types and therefore probably plays a greater role. In the future, it might be a viable approach to activate VRAC to enhance the immune response. Possible ways to do this have already been described in the new work.
"The field is incredibly hot," says Thomas Jentsch, "and our discovery offers completely new perspectives for both, infection research and cancer research.”

Zhou C., Chen X., Planells-Cases R., Chu J., Wang L., Cao L., Li Z., López-Cayuqueo K.I., Xie Y., Ye S., Wang X., Ullrich F., Ma S., Fang Y., Zhang X., Qian Z., Liang X., Cai S., Jiang Z., Zhou D., Leng Q., Xiao T.S., Lan K., Yang J., Li H., Peng C., Qiu Z., Jentsch T.J., Xiao H. (2020). Transfer of cGAMP into bystander cells by LRRC8 volume-regulated anion channels augments STING-mediated interferon responses and anti-viral immunity. Immunity, in press.  

Text Press Release: Beatrice Hamberger

Prof. Dr. Dr.Thomas Jentsch
Department Physiology and Pathology of Ion Transport
Leibniz-Forschungsinstitut für Molekulare Pharmakologie  (FMP) und Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Tel.: +49 30 9406 2961

Public Realations
Silke Oßwald
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)
13125 Berlin, Campus Berlin-Buch
E-Mail: osswald(at)

The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) is part of the Forschungsverbund Berlin e.V. (FVB), who legally represents eight non-university research institutes - members of the Leibniz Association - in Berlin. The institutions pursue common interests within the framework of a single legal entity while maintaining their scientific autonomy. More than 1,900 employees work within the research association. The eight institutes were founded in 1992 and emerged from former institutes of the GDR Academy of Sciences.

Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Germany
+4930 94793 - 100 
+4930 94793 - 109 (Fax)

Like many sites, we use cookies to optimize the user's browsing experience. Data Protection OK